Price Data
| Stock |
Price |
1D |
7D |
30D |
3M |
52wkHi |
RSI |
Status |
Action |
| IQV |
$165.62 |
-2.2% |
-6.5% |
-31.4% |
-23.8% |
-32.2% |
25↓ |
🟢 Deeply Oversold |
🔍 Research |
Legend
- RSI
↓ = Oversold (<30) - potential buying opportunity
- 52wkHi = -32.2% from $244.29 peak
- 52wk Low = $135.97 (Apr 9, 2025)
- SMA20 = $199.29 (price is -16.9% below SMA)
Price vs Last Deep Dive (02/15)
| Metric |
02/15 |
02/22 |
Change |
| Price |
$166.94 |
$165.62 |
-0.8% |
| RSI |
14 |
25.5 |
+11.5 (improving) |
| SMA20 |
N/A |
$199.29 |
— |
Company Overview
One-Liner
IQVIA provides data analytics, technology solutions, and contract research services to the life sciences industry.
Business Model
| Question |
Answer |
| What they sell |
Clinical trial management (CRO), healthcare data/analytics, technology platforms, commercial services |
| Who pays |
Pharma companies (90% of top 25 are clients), biotech firms, medical device companies, government agencies |
| Revenue model |
Long-term contracts (CRO), SaaS subscriptions (analytics), project-based (consulting) |
| How sticky |
Very high — multi-year CRO contracts, deeply embedded analytics platforms, proprietary data moat |
Key Segments
| Segment |
Revenue % |
Growth |
Notes |
| R&D Solutions (R&DS) |
55% |
+4.3% YoY |
Clinical trial management, project monitoring — $8,896M in 2025 |
| Technology & Analytics (TAS) |
40% |
+7.6% YoY |
Cloud apps, real-world evidence, data analytics — $6,626M in 2025 |
| Contract Sales & Medical (CSMS) |
5% |
Flat |
HCP engagement, scientific strategy — $788M in 2025 (merging into TAS in 2026) |
Geographic Mix
| Region |
Revenue % |
Notes |
| Americas |
~50% |
US is core market |
| Europe/MEA |
~35% |
Strong CRO presence |
| Asia-Pacific |
~15% |
Growing |
Competitive Analysis
Industry Position
| Question |
Answer |
| Market share |
33% of global health analytics; #1 or #2 CRO globally |
| Market size (TAM) |
$84.6B CRO market (2025), growing to $126B by 2030 |
| Growth rate |
8.3% CAGR (CRO market) |
| Key competitors |
ICON plc ($7.8B rev), Thermo Fisher (PPD), LabCorp (Covance), Charles River Labs, Medpace |
| Position |
Leader — unique hybrid combining CRO + data/analytics |
Competitive Moat
| Moat Type |
Present? |
Evidence |
| Network effects |
🟢 |
More data from trials = better analytics = attracts more clients |
| Switching costs |
🟢 |
Multi-year contracts, deeply embedded platforms, proprietary data dependencies |
| Cost advantages |
🟢 |
Scale across 100+ countries, largest CRO workforce globally |
| Intangible assets |
🟢 |
Proprietary healthcare datasets covering 1B+ patient records, regulatory expertise |
| Efficient scale |
🟢 |
$16.3B revenue vs ICON's $7.8B — economies of scale in trial management |
Moat Assessment
Moat Width: Wide
Moat Trend: Widening (AI + data flywheel)
Summary:
IQVIA's unique combination of CRO services and proprietary healthcare data creates a competitive advantage no pure-play CRO or analytics firm can match. The data flywheel strengthens as more trials generate more proprietary data, feeding better analytics products. The AWS AI partnership further extends this advantage.
Management Assessment
Leadership
| Role |
Name |
Since |
Background |
Notes |
| CEO & Chairman |
Ari Bousbib |
Oct 2016 |
UPenn BA, Harvard MBA. Former CEO of IMS Health, CEO of Otis Elevator (UTC). Partner at Booz Allen Hamilton. |
Architect of Quintiles-IMS merger. Also on Home Depot board. |
| CFO |
Ron Bruehlman |
Aug 2020 |
40-year career. Former IMS Health CFO, UTC senior exec, ConocoPhillips. |
Deep financial ops experience. |
Founder Involvement
| Question |
Answer |
| Founder-led? |
No (merger-created company) |
| Founder ownership |
N/A |
| Skin in the game |
Bousbib has significant equity comp |
Capital Allocation
| Metric |
Track Record |
| M&A discipline |
Good — strategic tuck-ins to expand data/tech capabilities |
| Buyback timing |
Good — active repurchaser |
| R&D investment |
High — investing heavily in AI/agentic platforms |
| Debt management |
Moderate — $13B+ debt from merger, but generating strong FCF |
Red Flags
- Excessive exec compensation
- High turnover in key roles
- Related party transactions
- Aggressive accounting
- Net insider selling of -$39.8M (1 buy vs 11 sells) — not unusual for large-cap but worth noting
Financials
Key Metrics
| Metric |
2025 |
2024 |
2023 |
Trend |
| Revenue |
$16,310M |
~$15,480M |
~$14,980M |
📈 |
| Revenue Growth YoY |
+5.4% |
+3.3% |
+3.4% |
📈 Accelerating |
| Adj. EBITDA |
~$3,800M |
~$3,600M |
~$3,500M |
📈 |
| Adj. EPS |
$11.92 |
$11.13 |
$10.37 |
📈 |
| Net Debt/EBITDA |
~3.4x |
~3.5x |
~3.6x |
📈 Deleveraging |
Quality Checks
| Check |
Status |
Notes |
| FCF positive? |
🟢 |
Strong free cash flow generation |
| Profitable? |
🟢 |
Consistently profitable, growing EPS |
| Debt manageable? |
🟡 |
~$13B debt but generating $2B+ FCF, deleveraging |
| Cash runway |
N/A |
Profitable, not burning cash |
Revenue Quality
| Factor |
Assessment |
| Recurring % |
~70%+ (long-term CRO contracts + SaaS analytics) |
| Customer concentration |
Low — 90% of top 25 pharma are clients |
| Contract length |
Multi-year (CRO trials avg 2-5 years) |
| NRR/NDR |
Not disclosed, but high retention given switching costs |
Leading Indicators
| Indicator |
Value |
Signal |
| Revenue Acceleration |
-2.84% |
🟡 Decelerating slightly |
| YoY Growth |
+5.2% |
🟡 Moderate |
| Earnings Beat Rate |
100% |
🟢🟢 STRONG |
| Insider Trading |
-$39.8M net (1 buy, 11 sells) |
🟡 Neutral |
| Composite |
0.4 |
🟡 Neutral |
Valuation
Current Multiples
| Metric |
Current |
5Y Avg |
Industry Avg |
| P/E (trailing) |
~14x |
~50x |
~25x |
| P/E (forward) |
~13x |
~25x |
~20x |
| EV/EBITDA |
~10x |
~15x |
~14x |
| P/S |
~1.7x |
~3.5x |
~3.0x |
Note: Current multiples remain compressed at near-bottom levels. Market cap ~$27B.
Historical Range
| Metric |
Current |
5Y High |
5Y Low |
% of Range |
| P/E |
~13x |
~292x |
~16x |
Near bottom |
| EV/EBITDA |
~10x |
~20x |
~10x |
At bottom |
Fair Value Estimate
| Method |
Fair Value |
Upside/Downside |
| DCF (historical avg P/E 25x fwd) |
$320 |
+93% |
| Comps (18x fwd EPS) |
$231 |
+39% |
| Conservative (15x fwd EPS) |
$193 |
+16% |
Fair Value Estimate: $210-$230 (based on 16-18x forward EPS of $12.70 midpoint guidance)
Bull Case
Why This Could Work (5 Reasons)
Extreme valuation compression
- Evidence: Trading at ~13x forward P/E vs 5Y avg ~25x. EV/EBITDA at 5Y lows.
- Implication: If multiple normalizes even halfway, stock goes to $200+.
AI/agentic platform catalyst
- Evidence: Strategic AWS partnership, deploying agentic AI across clinical trials and analytics.
- Implication: Could accelerate TAS growth (already +7.6%) and expand margins.
Irreplaceable data moat
- Evidence: 1B+ patient records, 33% health analytics share, 90% of top pharma are clients.
- Implication: Data advantage compounds with AI capabilities — no competitor can replicate this dataset.
CRO market tailwinds
- Evidence: CRO market growing at 8.3% CAGR to $126B by 2030. Pharma R&D spend increasing.
- Implication: Structural growth as pharma outsources more clinical trials.
Consistent execution
- Evidence: 100% earnings beat rate, steady revenue growth acceleration (3.3% -> 5.4%), deleveraging.
- Implication: Management delivering despite macro headwinds.
Upside Scenario
| If This Happens |
Stock Could |
| AI platform drives TAS growth to 10%+ |
$230 (+39%) — re-rate to 18x fwd |
| Broader market recovery + multiple normalization |
$250 (+51%) — return to Jan 2026 levels |
Bear Case
What Could Go Wrong (4 Risks)
Clinical trial cancellations accelerating
- How it plays out: Biotech funding pullback leads to more contract cancellations, pressuring R&DS backlog.
- Probability: Medium — already impacting guidance narrative.
Debt burden in rising rate environment
- How it plays out: ~$13B debt with $80M step-up in interest expense in 2026. Refinancing risk.
- Probability: Medium — manageable with FCF but limits financial flexibility.
2026 EPS guidance below expectations
- How it plays out: $12.55-$12.85 guidance disappointed consensus. Market may not trust management outlook.
- Probability: High — already occurring, driving selloff.
Competition from specialized AI analytics
- How it plays out: New entrants with superior AI capabilities erode TAS market share.
- Probability: Low — data moat is very hard to replicate.
Thesis Killers
- R&DS backlog declining for 3+ consecutive quarters
- Major pharma client defecting to competitor
- Debt covenant breach or downgrade to junk
Downside Scenario
| If This Happens |
Stock Could |
| Guidance cut + continued cancellations |
$135 (-18%) — retest April 2025 lows |
| Recession hits pharma R&D budgets |
$120 (-28%) — new 52-week lows |
Market-Moving News
Historical (What Moved This Stock Before)
| Date |
Event |
Impact |
Market Reaction |
Lesson |
| Jan 2026 |
Strong rally from $225 to $247 |
+10% |
Overbought (RSI 86) |
IQVIA overshoots in both directions |
| Feb 5, 2026 |
Q4 2025 earnings + 2026 guidance cut |
-22% in days |
Massive selloff despite revenue beat |
Guidance > beats for this stock |
| Apr 2025 |
Tariff/macro selloff |
-25% |
Hit $136 52wk low |
Recovered fully in 9 months |
| Nov 2025 |
IQVIA cuts 2025 EBITDA guidance |
-5% |
Moderate selloff |
Guidance sensitivity is a pattern |
Recent News
| Date |
Headline |
Source |
Impact |
Relevance |
| Feb 5, 2026 |
Q4 2025 earnings beat but 2026 EPS guidance below consensus ($12.55-$12.85) |
BusinessWire |
🔴 |
Triggered -22% selloff |
| Feb 12, 2026 |
Stock hit $156.67 intraday low, volume 7M (5x normal) |
Market data |
🔴 |
Capitulation volume |
| Dec 2025 |
AWS named Preferred Agentic Cloud Provider for AI platform |
Nasdaq |
🟢 |
Long-term AI catalyst |
| Feb 2026 |
Segment restructure: CSMS merging into TAS (renamed "Commercial Solutions") |
SEC filings |
🟡 |
Operational simplification |
News Patterns
IQVIA is extremely sensitive to forward guidance. Revenue beats don't matter if guidance disappoints. The stock overshoots in both directions — rallied from $136 to $247 (+82%) in 9 months, then dropped -32% in 5 weeks. Capitulation volume suggests forced/institutional selling. RSI has recovered from extreme 14 to 25.5 — stabilization signal.
| Symbol |
Name |
Relationship |
Notes |
| IHI |
iShares U.S. Medical Devices ETF |
Contains IQV |
Healthcare technology exposure |
| XLV |
Health Care Select SPDR |
Sector ETF |
Broad healthcare benchmark |
| VHT |
Vanguard Health Care ETF |
Contains IQV |
Diversified healthcare |
| XBI |
SPDR S&P Biotech ETF |
Customer proxy |
Biotech health = CRO demand |
Sector Context
Healthcare data/analytics is holding up better than pure tech. The selloff appears IQVIA-specific (guidance miss) rather than sector-wide. XLV is relatively stable. This is stock-specific, not systemic.
Cross-References (Where This Appears in Our System)
| Location |
File |
Context |
| Scans |
Not found |
Not currently in any scan watchlist |
| Candidates |
Not found |
Not in any theme folder |
| Theses |
Not found |
No active thesis |
| Ideas |
Not found |
No external mentions |
| Watchlists |
Not found |
Not tracked in any watchlist |
| Holdings |
Not found |
Not currently held |
Note: IQV is entirely new to our research system. Consider adding to healthcare/defensive candidate list.
| Ticker |
Why Related |
Suggested Placement |
Priority |
Notes |
| ICON |
#2 CRO competitor ($7.8B rev) |
candidates/biotech/ |
🟡 |
Compare CRO valuations |
| VEEV |
Key tech partner (Veeva CRM) |
candidates/cloud-saas/ |
🟡 |
IQVIA uses Veeva Clinical Suite |
| TMO |
CRO competitor (Thermo Fisher/PPD) |
Already tracked |
🟢 |
Comp for R&DS segment |
| MEDP |
Pure-play mid-cap CRO |
candidates/biotech/ |
🟡 |
Higher-growth CRO alternative |
| CRL |
Preclinical CRO (Charles River) |
candidates/biotech/ |
🟡 |
Different CRO niche |
Catalysts & Timing
Upcoming Catalysts
| Date |
Event |
Impact |
Watch For |
| Q1 2026 |
First quarter under new segment structure |
🟡 |
TAS + CSMS combined metrics |
| Mid-2026 |
AI platform deployment milestones |
🟢 |
AWS partnership deliverables |
| Apr/May 2026 |
Q1 2026 earnings |
🟢 |
Whether guidance was conservative or real |
| Ongoing |
Biotech funding environment |
🟡 |
Determines CRO demand pipeline |
Key Dates
| Event |
Frequency |
Next Date |
| Earnings |
Quarterly |
Late Apr / Early May 2026 |
| Investor Day |
Annual |
TBD |
Entry Strategy
Position Sizing
| Conviction |
Allocation |
| Speculative |
0% (research only) |
| Low |
1-2% |
| Medium |
3-5% |
| High |
5-10% |
My conviction: Medium
Target allocation: 2-3%
Entry Approach
| Strategy |
Details |
| Entry zone |
$155 - $170 (current levels) |
| Starter position |
1% of portfolio (~$500-$1,000) |
| Add on |
Stabilization above $175 with RSI > 30 |
| Full position at |
Confirmation of Q1 2026 guidance being met |
Technical Levels
| Level |
Price |
Notes |
| Support 1 |
$157 |
Feb 12 intraday low area |
| Support 2 |
$136 |
April 2025 52-week low |
| Resistance 1 |
$187 |
Feb 6 close (post-earnings) |
| Resistance 2 |
$230 |
Pre-earnings Jan level |
| 52-week high |
$244.29 |
Jan 2026 |
| 52-week low |
$135.97 |
Apr 9, 2025 |
Research Checklist
Fundamentals
- Review most recent earnings (Q4 2025)
- Understand revenue drivers and segments
- Review 2026 guidance
- Read Q4 2025 earnings call transcript in detail
Competitive
- Map competitive landscape (ICON, TMO, MEDP, CRL)
- Assess moat durability (Wide - data + scale)
- Check CRO industry backlog trends
Management
- Research CEO/CFO background
- Check insider activity (-$39.8M net selling)
- Review capital allocation history
Valuation
- Review historical multiples (near 5Y lows)
- Compare to peers
- Identify entry/exit zones
Risk
- Write bear case
- Identify thesis-killers
- Set stop-loss level ($134)
Sources
| Type |
Link |
Notes |
| Investor Relations |
https://ir.iqvia.com |
Official filings |
| Q4 2025 Earnings |
BusinessWire Feb 5, 2026 |
Revenue beat, EPS guidance light |
| AWS Partnership |
Nasdaq press release Dec 2025 |
Agentic AI platform |
| CRO Market |
MarketsandMarkets |
$84.6B -> $126B by 2030 |
Research Log
| Date |
Update |
| 2026-02-15 |
Created deep dive. RSI 14 extreme oversold. -31% 30D on guidance miss. Wide moat, 100% earnings beat rate, fair value $210-$230. |
| 2026-02-22 |
Price refresh. Price $165.62 (-0.8% from 02/15). RSI improved from 14 to 25.5 — stabilization. 30D still -31.4%. SMA20 $199.29. Still in research/watch mode. |
The Gold
Key Discoveries
| Discovery |
Implication |
| RSI 14 with 100% earnings beat rate |
Selloff is guidance-driven, not fundamental deterioration |
| P/E at ~13x fwd vs 5Y avg ~25x |
If even partial re-rating occurs, 30-50% upside |
| 7M volume on Feb 12 (5x normal) |
Institutional/forced selling — capitulation signature |
| Recovered from $136 to $247 in 9 months last year |
IQVIA bounces hard from oversold levels |
| RSI improved from 14 to 25.5 by 02/22 |
Possible stabilization forming; watch for RSI > 30 as signal |
Open Questions
- Is the Q4 cancellation trend in R&DS worsening or stabilizing?
- How much of the selloff is tax-loss harvesting vs fundamental concern?
- What is the AI platform revenue contribution timeline?
- Is the $13B debt a concern given rising refinancing costs?
- Would biotech funding winter meaningfully impact CRO demand?
Mistakes (If Applicable)
| Mistake |
Lesson |
| N/A — first research |
Watch for falling knife risk. Wait for RSI stabilization above 20-25 before committing. |